1. Кохно А.В., Паровичникова Е.Н., Михайлова Е.А., Савченко В.Г. Алгоритмы обследования и протоколы лечения больных с различными формами миелодиспластических синдромов
В кн.: Савченко В.Г., ред. Программное лечение заболеваний системы крови. Сборник алгоритмов диагностики и протоколов лечения заболеваний системы крови. М.: Практика; 2018.
References
1. Kokhno A.V., Parovichnikova E.N., Mikhaylova E.A., Savchenko V.G. Myelodysplastic syndromes and aplastic anemia. In: Savchenko V.G., ed. Programs of treatment of diseases of the blood system. Collection of diagnostic algorithms and protocols of treatment of diseases of the blood system. Moscow: Praktika; 2012: 83--150.
2. Cheson B.D., Greenberg P.L., Bennett J.M., Lowenberg B., Wijermans P.W., Nimer S.D., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006; 108(2): 419--25.
3. Della Porta M.G., Tuechler H., Malcovati L., Schanz J., Sanz G., Garcia-Manero G., et al. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia. 2015; 29(7): 1502--13.
4. Garcia-Manero G. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management. Am. J. Hematol. 2015; 90(9): 831--41.
5. Vardiman J.W., Thiele J., Arber D.A., Brunning R.D., Borowitz M.J., Porwit A., et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5): 937--51. doi: 10.1182/blood-2009-03-209262.
6. Greenberg P., Cox C., LeBeau M.M., Fenaux P., Morel P., Sanz G., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997; 89(6): 2079--88.
7. Malcovati L., Hellstrom-Lindberg E., Bowen D., Ades L., Cermak J., Del Canizo C., et al.; European Leukemia Net. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013; 122(17): 2943--64.
8. Odenike O., Onida F., Padron E. Myelodysplastic syndromes and myelodysplas-tic/myeloproliferative neoplasms: an update on risk stratification, molecular genetics, and therapeutic approaches including allogeneic hematopoietic stem cell transplantation. Am. Soc. Clin. Oncol. Educ. Book. 2015: e398--412.
9. Voso M.T., Fenu S., Latagliata R., Buccisano F., Piciocchi A., Aloe-Spiriti M.A., et al. Revised International Prognostic Scoring System (IPSS) predicts survival and leukemic evolution of myelodysplastic syndromes significantly better than IPSS and WHO Prognostic Scoring System: validation by the Gruppo Romano Mielodisplasie Italian Regional Database. J. Clin. Oncol. 2013; 31(21): 2671--7.
10. Greenberg P.L., Stone R.M., Al-Kali A., Bejar R., Bennett J.M., Bloomfield C.D., et al. NCCN (National Comprehensive Cancer Network). Clinical Practice Guidelines in Oncology. Myelodysplastic syndromes. Version 1.2016. http://NCCN.org